Patents by Inventor Charles M. Romfo

Charles M. Romfo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and agents for screening for compounds capable of modulating gene expression
    Patent number: 9068234
    Abstract: The invention relates to the fields of screening assays, compounds, and methods for altering gene expression and protein levels. In particular, the invention includes assays to screen for agents capable of modulating gene expression in a UTR-dependent manner and agents capable of modulating gene expression.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: June 30, 2015
    Assignee: PTC Therapeutics, Inc.
    Inventors: Liangxian Cao, Anuradha Mehta, Nikolai A. Naryshkin, Matthew C. Pellegrini, Charles M. Romfo, Panayiota Trifillis, Christopher R. Trotta
  • Methods for treating prostate conditions
    Patent number: 8703726
    Abstract: Methods for treating prostate cancer involving the administration of a compound that selectively inhibits pathological production of human vascular endothelial growth factor (VEGF) are described. Methods for treating benign prostatic hyperplasia involving the administration of a compound that selectively inhibits pathological production of human VEGF are also described. The compound may be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: April 22, 2014
    Assignee: PTC Therapeutics, Inc.
    Inventors: Liangxian Cao, Thomas W. Davis, Samit Hirawat, Harry H. Miao, Langdon Miller, Charles M. Romfo, Marla L. Weetall
  • METHODS FOR TREATING BREAST CANCER
    Publication number: 20120202801
    Abstract: Methods for treating breast cancer involving the administration of a compound that selectively inhibits pathological production of human vascular endothelial growth factor (VEGF) are described. The compound can be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatment.
    Type: Application
    Filed: May 27, 2010
    Publication date: August 9, 2012
    Inventors: Liangxian Cao, Thomas W. Davis, Samit Hirawat, Harry H. Miao, Langdon Miller, Charles M. Romfo, Marla L. Weetall
  • METHODS FOR TREATING PROSTRATE CONDITIONS
    Publication number: 20120178707
    Abstract: Methods for treating prostate cancer involving the administration of a compound that selectively inhibits pathological production of human vascular endothelial growth factor (VEGF) are described. Methods for treating benign prostatic hyperplasia involving the administration of a compound that selectively inhibits pathological production of human VEGF are also described. The compound may be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.
    Type: Application
    Filed: May 27, 2010
    Publication date: July 12, 2012
    Inventors: Liangxian Cao, Thomas W. Davis, Samit Hirawat, Harry H. Miao, Langdon Miller, Charles M. Romfo, Marla L. Weetall
  • Inhibition of VEGF translation
    Patent number: 8076353
    Abstract: In accordance with the present invention, methods for inhibiting the translation of VEGF and methods for decreasing VEGF level by inhibiting VEGF translation are provided. In another aspect of the invention, compounds that inhibit the 5?-UTR-dependent translation of VEGF and methods for identifying such compounds are provided.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: December 13, 2011
    Assignee: PTC Therapeutics, Inc.
    Inventors: Liangxian Cao, Thomas W. Davis, Charles M. Romfo, Christopher R. Trotta